Evommune, Inc.
EVMN NYSE Pharmaceutical Preparations Financials FY2024–FY2025
What Evommune, Inc. does
No business description yet.
- Legal name
- Evommune, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Accession · CIK
- 0001193125-26-093932
0002044725
Revenue and margins
Evommune, Inc. had $13.0M of revenue in fiscal 2025, up 85.7% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$76.7M in fiscal 2025, −589.8% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Evommune, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 306.9%.
Balance sheet
Cash, debt and the ratios that show how comfortably Evommune, Inc. can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $72.0M | $149M |
| Current ratio | 2.6x | 8.6x |
| Quick ratio | 2.6x | 8.6x |
| Total assets | $76.1M | $225M |
| Total liabilities | $28.5M | $19.4M |
| Shareholders' equity | −$144M | $206M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✓ |
| Cash from operations exceeds net income | ✓ | ✕ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✓ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | ✕ |
| F-score | — / 3 | 2 / 7 |
| Accruals ratio | −11.3% | 5.0% |
| Altman Z'' | −14.05 | 9.47 |
2 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | $7.0M | $13.0M |
| Research and development | $64.2M | $74.0M |
| Operating income | −$70.0M | −$81.1M |
| Pretax income | −$68.3M | −$68.9M |
| Income tax | $0.0M | $0.0M |
| Net income | −$66.8M | −$68.9M |
| Net income to common | −$68.3M | −$68.9M |
| Diluted EPS | −$45.29 | −$11.22 |
| Diluted shares | 0.00B | 0.01B |
| Cash flow | ||
| Cash from operations | −$58.2M | −$76.4M |
| Capital expenditure | $0.1M | $0.2M |
| Free cash flow | −$58.3M | −$76.7M |
| Depreciation and amortization | $0.5M | $0.6M |
| Stock-based compensation | $1.7M | $5.9M |
| Balance sheet | ||
| Cash and short-term investments | $72.0M | $149M |
| Finance lease liabilities | — | $0.5M |
| Current assets | $74.0M | $153M |
| Current liabilities | $28.0M | $17.9M |
| Property and equipment, net | $1.3M | $1.0M |
| Total assets | $76.1M | $225M |
| Total liabilities | $28.5M | $19.4M |
| Shareholders' equity | −$144M | $206M |
| Margins | ||
| Operating margin | −1,000.2% | −623.6% |
| EBITDA margin | −993.0% | −619.0% |
| Net margin | −954.4% | −529.8% |
| FCF margin | −832.6% | −589.8% |
| Returns | ||
| Return on capital employed | −145.6% | −39.2% |
| Return on equity | — | −224.6% |
| Return on assets | −87.8% | −45.8% |
| Return on tangible equity | — | −33.5% |
| Growth | ||
| Revenue growth | — | 85.7% |
| Share count change | — | 306.9% |
| Financial health | ||
| Current ratio | 2.6x | 8.6x |
| Quick ratio | 2.6x | 8.6x |
| Capital allocation | ||
| Capex / revenue | 1.3% | 1.8% |
| Stock comp / revenue | 24.6% | 45.0% |
| Quality scores | ||
| Piotroski F-score | — | 2.0 |
| Altman Z'' | −14.1 | 9.5 |
| Accruals ratio | −11.3% | 5.0% |
Source: SEC EDGAR XBRL filings (CIK 0002044725). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.